Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF) Prop
Post# of 31
(Total Views: 163)
Posted On: 07/29/2021 4:07:13 PM
Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF) Proprietary Imaging System Set to Advance Bladder Cancer Visualization
- Approximatively 75-85% of patients with confirmed cases of bladder cancer are diagnosed with non-muscle invasive (“NMIBC”)
- Imagin Medical’s innovative technology is targeting this type of bladder cancer and set to be completed in 2022
- Blue light cystoscopy helps surgeons visualize the cancerous cells that are not detected by white light, enabling an improved resection
Non-muscle-invasive bladder cancer (“NMIBC”) is a type of bladder cancer that has not infiltrated the other muscle tissues inside the bladder or spread to the lymph nodes. Approximately 75-85% of patients presenting with bladder cancer are diagnosed with NMIBC. The most common symptoms of NMIBC which may prompt initial testing is blood in the urine (https://nnw.fm/86isJ).
The primary procedure used to detect bladder cancer is called a cystoscopy, which uses an endoscope and, typically, white light visualization. White light cystoscopy has been the standard for more than 90% of the procedures for decades and is beneficial in removing cancerous growths that protrude from the bladder wall. Yet, it is almost impossible to detect and resect cancerous cells that lay flat against the bladder, leaving some cells behind and causing a higher risk of recurrence. Approximately 50% of patients who have had a cystoscopy to remove NMIBC see their cancer return. Right now, approximately 724,000 people are living in fear that their bladder cancer will come back (https://nnw.fm/uKT19).
Blue Light Cystoscopy (“BLC”), used with and FDA approved imaging agent that fluoresces the cancer cells, was introduced in 2010. Although proven to be more effective in identifying cancerous cells and reducing recurrence, blue light is still only used in approximately 10% of bladder cancer procedures due to training, cost and ease-of-use issues.
To address these issues, Imagin Medical (CSE: IME) (OTCQB: IMEXF) has developed the i/Blue Imaging System(TM), an innovative technology designed to significantly improve the way surgeons visualize cancerous cells for more accurate bladder resection. This patented technology allows for white and blue light images to be projected side-by-side simultaneously, enabling better surgical technique. The i/Blue System will attach to most endoscopes currently on the market, protecting hospitals’ investment in instruments they already own and enabling their adoption of blue light cystoscopy at a significant cost savings.
Imagin Medical’s technology has entered the manufacturing stage with the company’s partner, Lighthouse Imaging, an FDA-registered and ISO 13485:2016 certified manufacturer. The i/Blue Imaging System is expected to be completed in 2022.
With the i/Blue Imaging System, Imagin Medical is poised to establish a new standard in bladder cancer visualization by radically changing how cystoscopies are performed and ultimately helping improve patients’ lives and long-term outlook. Imagin Medical’s target is estimated to be a $400M portion of the global endoscopy market valued at $25.59 billion in 2019 and is expected to grow at a CAGR of 6.6 percent to reach a total estimated value of $35.23 billion by 2024 (https://nnw.fm/7Fbxl).
For more information, visit the company’s website at www.ImaginMedical.com.
NOTE TO INVESTORS: The latest news and updates relating to IMEXF are available in the company’s newsroom at https://nnw.fm/IMEXF
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
- Approximatively 75-85% of patients with confirmed cases of bladder cancer are diagnosed with non-muscle invasive (“NMIBC”)
- Imagin Medical’s innovative technology is targeting this type of bladder cancer and set to be completed in 2022
- Blue light cystoscopy helps surgeons visualize the cancerous cells that are not detected by white light, enabling an improved resection
Non-muscle-invasive bladder cancer (“NMIBC”) is a type of bladder cancer that has not infiltrated the other muscle tissues inside the bladder or spread to the lymph nodes. Approximately 75-85% of patients presenting with bladder cancer are diagnosed with NMIBC. The most common symptoms of NMIBC which may prompt initial testing is blood in the urine (https://nnw.fm/86isJ).
The primary procedure used to detect bladder cancer is called a cystoscopy, which uses an endoscope and, typically, white light visualization. White light cystoscopy has been the standard for more than 90% of the procedures for decades and is beneficial in removing cancerous growths that protrude from the bladder wall. Yet, it is almost impossible to detect and resect cancerous cells that lay flat against the bladder, leaving some cells behind and causing a higher risk of recurrence. Approximately 50% of patients who have had a cystoscopy to remove NMIBC see their cancer return. Right now, approximately 724,000 people are living in fear that their bladder cancer will come back (https://nnw.fm/uKT19).
Blue Light Cystoscopy (“BLC”), used with and FDA approved imaging agent that fluoresces the cancer cells, was introduced in 2010. Although proven to be more effective in identifying cancerous cells and reducing recurrence, blue light is still only used in approximately 10% of bladder cancer procedures due to training, cost and ease-of-use issues.
To address these issues, Imagin Medical (CSE: IME) (OTCQB: IMEXF) has developed the i/Blue Imaging System(TM), an innovative technology designed to significantly improve the way surgeons visualize cancerous cells for more accurate bladder resection. This patented technology allows for white and blue light images to be projected side-by-side simultaneously, enabling better surgical technique. The i/Blue System will attach to most endoscopes currently on the market, protecting hospitals’ investment in instruments they already own and enabling their adoption of blue light cystoscopy at a significant cost savings.
Imagin Medical’s technology has entered the manufacturing stage with the company’s partner, Lighthouse Imaging, an FDA-registered and ISO 13485:2016 certified manufacturer. The i/Blue Imaging System is expected to be completed in 2022.
With the i/Blue Imaging System, Imagin Medical is poised to establish a new standard in bladder cancer visualization by radically changing how cystoscopies are performed and ultimately helping improve patients’ lives and long-term outlook. Imagin Medical’s target is estimated to be a $400M portion of the global endoscopy market valued at $25.59 billion in 2019 and is expected to grow at a CAGR of 6.6 percent to reach a total estimated value of $35.23 billion by 2024 (https://nnw.fm/7Fbxl).
For more information, visit the company’s website at www.ImaginMedical.com.
NOTE TO INVESTORS: The latest news and updates relating to IMEXF are available in the company’s newsroom at https://nnw.fm/IMEXF
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)